|Bid||78.40 x 0|
|Ask||78.90 x 0|
|Day's range||78.43 - 80.50|
|52-week range||77.00 - 124.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||23.24|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BATM (LSE: BVC) (TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has developed a new method for the rapid and comprehensive diagnosis of tuberculosis ("TB"). The testing and validation phase, which is expected to commence in the second half of this year, will be fully funded under a programme of the Stop TB Partnership, an international alliance comprising a wide range of governmental and non-governmental organisations.
BATM Advanced Communications Limited (LSE: BVC) (TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has launched a new molecular diagnostics kit that uses self-collected saliva samples to test for SARS-CoV-2 (COVID-19). This significantly improves the sample collection process compared with existing swabbing methods while, as an RT-PCR test, maintaining diagnostic accuracy. The Group has commenced taking orders and expects to begin delivering the kit in April.